



JUN 26 2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**

Equivalent of Form PTO/SB/08a (01-08)

Approved for use through 03/31/2001

**FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Use as many sheets as necessary.*

Sheet 1 of 3

**Complete if Known**

Application Number	10/782,664
Filing Date	February 18, 2004
First Named Inventor	MONTERO-JULIAN, Felix A.
Art Unit	1644
Examiner Name	DIBRINO, Marianne
Attorney Docket Number	2512.0210001/KWM-C-K (2052-183)

---

**U.S. PATENT DOCUMENTS**

---

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document
		Number-Kind Code <sup>2</sup> (If Known)	MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
M.D.J.	US1	4,017,597	04/12/1977	Reynolds
	US2	4,208,479	06/17/1980	Zuk <i>et al.</i>
	US3	4,912,030	03/27/1990	Weiss <i>et al.</i>
	US4	5,187,065	02/16/1993	Schutzer
	US5	5,514,557	05/07/1996	Moghaddam
	US6	5,534,416	07/09/1996	Millard <i>et al.</i>
	US7	5,583,031	12/10/1996	Stern
	US8	5,599,720	02/04/1997	Ekins
	US9	5,759,774	06/02/1998	Hackett <i>et al.</i>
	US10	5,919,639	07/06/1999	Humphreys <i>et al.</i>
	US11	5,956,532	09/21/1999	Arita
	US12	6,046,013	04/04/2000	Tidey <i>et al.</i>
	US13	6,143,517	11/07/2000	Young
	US14	6,225,042	05/01/2001	Cai <i>et al.</i>
	US15	6,270,772	08/07/2001	Burrows <i>et al.</i>
	US16	6,355,479	03/12/2002	Webb <i>et al.</i>
	US17	6,419,931	07/16/2002	Vitiello <i>et al.</i>
	US18	6,485,913	11/26/2002	Becker <i>et al.</i>
	US19	6,727,093	04/27/2004	Diamond
V M.D.J.	US20	2002/006903 A1	01/17/2002	Schneck <i>et al.</i>

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code*Number/Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	RELEVANT PATENT DOCUMENTS	
						T4	Abs
	FP1	WO 92/07052 A1	05/14/1992	Immulogic Pharma. Corp.; Merck & Co., Inc.			
/M.D./	FP2	WO 94/11738 A1	05/26/1994	Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.			Abs
	FP3	WO 95/04817 A1	02/16/1995	Cytel Corporation			
	FP4	WO 97/00067 A1	01/03/1997	University of Victoria			
	FP5	WO 97/04085 A1	July 15, 1997	Boehringer Mannheim GmbH	2 / 6 / 97		Abs
	FP6	WO 97/09429 A2	03/13/1997	Corixa Corporation			
/M.D./	FP7	WO 98/23690 A1	06/04/1998	Eastman Chemical Co.			

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kind Codes. USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.16). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is estimated to be 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for Form 1449/PTO</p> <p><b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i></p>			
<b>Complete if Known</b>			
Application Number		10/782,664	
Filing Date		February 18, 2004	
First Named Inventor		MONTERO-JULIAN, Felix A.	
Art Unit		1644	
Examiner Name		DIBRINO, Marianne	
Sheet	2	of	2
		Attorney Docket Number	
		2512.0210001/KWM/C-K (2052-183)	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/M.D./	FP8	EP 0 958 834 A1	11/24/1999	Meiji Milk Production Co. Ltd.		T <sup>6</sup>
	FP9	WO 00/15665 A2	03/23/2000	Pedersen, <i>et al.</i>		
	FP10	EP 1 138 766 A2	10/04/2001	Toray Industries, Inc.		
	FP11	WO 01/90747 A2	11/29/2001	Sunol Molecular Corporation		
	FP12	WO 03/040299 A2	05/15/2003	Commissariat à L'Energie Atomique; Sedac Therapeutics		Abs
/M.D./	FP13	WO 2004/094458 A2	11/04/2004	University of Massachusetts; Massachusetts Institute of Technology		

827035\_1.DOC

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).<sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
Sheet	I	of	5	Attorney Docket Number	2512.0210001/KWM/C-K (2052-183)

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
/M.D./	NPL1	"2006 Annual Immune Epitope Database and Discovery Workshop Meeting Report Executive Summary," at <i>The Third Annual Immune Epitope Database and Discovery Workshop</i> held on November 7 and 8, 2006 in North Bethesda, Maryland, 3 pages (January 2007)			
	NPL2	Arnold, P.Y., <i>et al.</i> , "The Majority of Immunogenic Epitopes Generate CD4 <sup>+</sup> T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues," <i>J. Immunol.</i> 169:739-749, The American Association of Immunologists (July 2002)			
	NPL3	Belmares, M.P., <i>et al.</i> , "Structural Factors Contributing to DM Susceptibility of MHC Class II/Peptide Complexes," <i>J. Immunol.</i> 169:5109-5117, The American Association of Immunologists (November 2002)			
	NPL4	Bercovici, N., <i>et al.</i> , "New Methods for Assessing T-Cell Responses," <i>Clin. Diagn. Lab. Immunol.</i> 7:859-864, American Society for Microbiology (2000)			
	NPL5	Boder, E.T., <i>et al.</i> , "Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide," <i>Dept. Chem. Biomol. Eng. Depart. Papers (CBE)</i> 1-25, University of Pennsylvania (November 2005)			
	NPL6	Bodinier, M., <i>et al.</i> , "Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding," <i>Nature Medicine</i> 6:707-710, Nature Publishing Group (2000); "Errata," <i>Nature Medicine</i> 7:129, Nature Publishing Group (2001)			
	NPL7	Burgess, W.H., <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>J. Cell Biol.</i> 111:2129-2138, Rockefeller University Press (1990)			
	NPL8	Buus, S., <i>et al.</i> , "The Relation Between Major Histocompatibility Complex (MHC) Restriction and the Capacity of <i>Ia</i> to Bind Immunogenic Peptides," <i>Science</i> 235:1353-1358, American Association for the Advancement of Science (1987)			
↓	NPL9	Call, M.E., <i>et al.</i> , "Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum," <i>EMBO J.</i> 23:2348-2357, Oxford University Press (June 2004)			
/M.D./	NPL10	Call, M.E., and Wucherpfennig, K.W., "The T Cell Receptor: Critical Role of the Membrane Environment in Receptor Assembly and Function," <i>Annu. Rev. Immunol.</i> 23:101-125, Annual Reviews (April 2005)			

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not to be considered. Copy this line and the next line and attach to application.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to use a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is provided for the use of the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
				Attorney Docket Number	2512.0210001/KWM/C-K (2052-183)
Sheet	2	of	5		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T <sup>2</sup>
/M.D./	NPL11	Constantin, C.M., <i>et al.</i> , "Major Histocompatibility Complex (MHC) Tetramer Technology: An Evaluation," <i>Biol. Res. Nurs.</i> 4:115-127, Sage Publications, Inc. (October 2002)			
	NPL12	Dutoit, V., <i>et al.</i> , "Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR," <i>J. Immunol.</i> 168:1167-1171, American Association of Immunologists (February 2002)			
	NPL13	Eichmüller, S., <i>et al.</i> , "A new method for double immunolabeling with primary antibodies from identical species," <i>J. Immunol. Methods</i> 190:255-265, Elsevier Science Ltd. (1996)			
	NPL14	Flad, T., <i>et al.</i> , "Direct Identification of Major Histocompatibility Complex Class I-bound Tumor-associated Peptide Antigens of a Renal Carcinoma Cell Line by a Novel Mass Spectrometric Method," <i>Cancer Res.</i> 58:5803-5811, American Association for Cancer Research (1998)			
	NPL15	Garboczi, DN., <i>et al.</i> , "HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in <i>Escherichia coli</i> and complexed with single antigenic peptides," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:3429-3433, National Academy of Sciences. (1992)			
	NPL16	Godkin, A.J., <i>et al.</i> , "Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immuno genic Flanking Region Sequence Preferences that Reflect Antigen Processing Rather than Peptide-MHC Interactions," <i>J. Immunol.</i> 166:6720-6727, American Association of Immunologists (June 2001)			
	NPL17	Gretz, T.F., and Schneck, J.P., "Development and Use of Multimeric Major Histocompatibility Complex Molecules," <i>Clin. Diagn. Lab. Immunol.</i> 9:216-220, American Society for Microbiology (March 2002)			
	NPL18	Herr, W., <i>et al.</i> , "Detection and quantification of blood-derived CD8 <sup>+</sup> T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens," <i>J. Immunol. Methods</i> 191:131-142, North-Holland Publishing Co. (1996)			
↓	NPL19	Herr, W., <i>et al.</i> , "The use of computer-assisted video image analysis for the quantification of CD8 <sup>+</sup> T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens," <i>J. Immunol. Methods</i> 203:141-152 North-Holland Publishing Co. (1997)			
/M.D./	NPL20	Hunt, D.F., <i>et al.</i> , "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263, American Association for the Advancement of Science (1992)			

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Application or Reference Information may be used. <sup>2</sup> Applicant is required to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.14. The information is being collected by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is being made under 35 U.S.C. 122. The burden will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
Sheet	3	of	5	Attorney Docket Number	2512.0210001/KWM/C-K (2052-183)

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T <sup>2</sup>
/M.D./	NPL21	Jensen, P.E., <i>et al.</i> , "A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules," <i>J Immunol. Methods</i> 215:71-80, Elsevier Science Ltd. (1998)			
	NPL22	Klein, J., and Sato, A., "The HLA System - Second of Two Parts," <i>N. Engl. J. Med.</i> 343:782-786, Massachusetts Medical Society (September 2000)			
	NPL23	Kozono, H., <i>et al.</i> , "Production of soluble MHC class II proteins with covalently bound single peptides," <i>Nature</i> 369:151-154, Nature Publishing Group (1994)			
	NPL24	Lazar, E., <i>et al.</i> , "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Mol. Cell. Biol.</i> 8:1247-1252, American Society for Microbiology (1988)			
	NPL25	Male, D., "Chapter 2: Antibodies and Antigens," in <i>Immunology: An Illustrated Outline</i> , Bennet, D., ed., Gower Medical Publishing, London, England, p.19-36 (1986)			
↓	NPL26	Marin, M., <i>et al.</i> , "Cloning and Expression of a Single-Chain Antibody Fragment Specific for a Monomorphic Determinant of Class I Molecules of the Human Major Histocompatibility Complex," <i>Hybridoma</i> 14:443-451, Mary Ann Liebert, Inc. (1995)			
/M.D./	NPL27	McMichael, A.J., and Kelleher, A., "The arrival of HLA class II tetramers," <i>J. Clin. Invest.</i> 104:1669-1670, American Society for Clinical Investigation (1999)			
	NPL28	Merriam Webster OnLine Dictionary definition for the term "reconstitute"			
/M.D./	NPL29	Miller, J.E.W., <i>et al.</i> , "Rapid Determination of Class I Peptide Binding Motifs Using Codon-based Random Peptide Phage Display Libraries," <i>J. Cell. Biochem. Supp.</i> 8D:292, V116, Wiley-Liss (1994)			
/M.D./	NPL30	Nepom, G.T., <i>et al.</i> , "HLA Class II Tetramers: Tools for Direct Analysis of Antigen-Specific CD $^+$ T Cells," <i>Arthritis Rheum.</i> 46:5-12, Wiley-Liss, Inc. (January 2002)			

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered in reducing cost of this form with the understanding it will be subject to a fee if filed.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is in the interest (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
Sheet	4	of	5	Attorney Docket Number	2512.0210001/KWM/C-K (2052-183)

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T <sup>2</sup>
/M.D./	NPL31	Ogg, G.S., and McMichael, A.J., "HLA-peptide tetrameric complexes," <i>Curr. Opin. Immunol.</i> 10:393-396, Current Biology Publications (1998)			
	NPL32	Plytycz, B. and Seljelid, R., "MHC Molecules and Lymphocytes: Evolutionary Perspective," <i>Archivum Immunologiae et Therapiae Experimentalis</i> 46:137-142, Birkhäuser (1998)			
	NPL33	Reichstetter, S., <i>et al.</i> , "Distinct T Cell Interactions with HLA Class II Tetramers Characterize a Spectrum of TCR Affinities in the Human Antigen-Specific T Cell Response," <i>J. Immunol.</i> 165:6994-6998, The American Association of Immunologists (December 2000)			
	NPL34	Roitt, I.M., <i>et al.</i> , "Structure In Relation to Function," in <i>Immunology</i> , Gower Medical Publishing, London, page 5.7 (1985)			
	NPL35	Rötzscheck, O., <i>et al.</i> , "Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 96:7445-7450, National Academy of Sciences (1999)			
	NPL36	Sadegh-Nasseri, S., and McConnell, H.M., "A kinetic intermediate in the reaction of an antigenic peptide and I-E <sup>k</sup> ," <i>Nature</i> 337:274-276, Nature Publishing Group (1989)			
	NPL37	Seffernick, J.F., <i>et al.</i> , "Melamine Deaminase and Atrazine Chlorohydroxylase: 98 Percent Identical but Functionally Different," <i>J. Bacteriology</i> 183:2405-2410, American Society for Microbiology (2001)			
	NPL38	Sliz, P., <i>et al.</i> , "Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes," <i>J. Immunol.</i> 167:3276-3284, The American Association of Immunologists (September 2001)			
↓	NPL39	Sørensen, A.L., <i>et al.</i> , "Purification and Characterization of a Low-Molecular-Mass T-Cell Antigen Secreted by <i>Mycobacterium tuberculosis</i> ," <i>Infect. Immun.</i> 63:1710-1717, American Society For Microbiology (1995)			
/M.D./	NPL40	Stone, J.D., <i>et al.</i> , "T-Cell Activation by Soluble MHC Oligomers Can Be Described by a Two-Parameter Binding Model," <i>Biophys. J.</i> 81:2547-2557, Biophysical Society (November 2001)			

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne
				Attorney Docket Number	2512.0210001/KWM/C-K (2052-183)
Sheet	5	of	5		

<b>NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T <sup>2</sup>
/M.D./	NPL41	Sugita, M., <i>et al.</i> , "Assembly and Retention of CD1b Heavy Chains in the Endoplasmic Reticulum," <i>J. Immunol.</i> 159:2358-2365, American Association of Immunologists, Inc. (1997)				
	NPL42	Sylvester-Hvid, C., <i>et al.</i> , "Establishment of a quantitative ELISA capable of determining peptide – MHC class I interaction," <i>Tissue Antigens</i> 59:251-258, Blackwell Synergy (2002)				
	NPL43	Tao, M.H., and Morrison, S.L., "Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <i>J. Immunol.</i> 143:2595-2601, American Association of Immunologists (1989)				
	NPL44	Tissot, A.C., <i>et al.</i> , "Characterizing the functionality of recombinant T-cell receptors in vitro: a pMHC tetramer based approach," <i>J Immunol. Methods</i> 236:147-165, Elsevier Science Ltd. (2000)				
	NPL45	Tompkins, S.M., <i>et al.</i> , "A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins," <i>J Immunol. Methods</i> 163:209-216, Elsevier Science Ltd. (1993)				
	NPL46	Wells, J.A., "Additivity of Mutational Effects in Proteins," <i>Biochem.</i> 29:8509-8517, American Chemical Society (1990)				
	NPL47	Welsh, R.M., "Assessing CD8 T Cell Number and Dysfunction in the Presence of Antigen," <i>J. Exp. Med.</i> 193:F19-F22, The Rockefeller University Press (March 2001)				
↓	NPL48	Woll, M. M., <i>et al.</i> , "Direct Measurement of Peptide-Specific CD8 <sup>+</sup> T cells Using HLA-A2:1g Dimer for Monitoring the <i>In Vivo</i> Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients," <i>J. Clin. Invest.</i> 24:449-461, American Society for Clinical Investigation (July 2004)				
/M.D./	NPL49	Zarutskie, J.A., <i>et al.</i> , "A Conformational Change in the Human Major Histocompatibility Complex Protein HLA-DR1 Induced by Peptide Binding," <i>Biochemistry</i> 38:5878-5887, American Chemical Society (1999)				

827037\_1.DOC

Examiner Signature	/Marianne DiBrino/	Date Considered	02/20/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant may designate a language other than English (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.16. The information is mandatory to help or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 0.5 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.